Navigation Links
Novel Diabetes Drug Discovery Has Potential to Reverse Disease
Date:1/27/2009

WYNNEWOOD, Pa., Jan. 27 /PRNewswire/ -- A study released today in Endocrine Practice (2008;14:1075), the leading peer-reviewed journal for practicing endocrinologists in the US and 65 countries, reports a ground breaking discovery with the potential to reverse type 1 and 2 diabetes. Scientists at CureDM, Inc. have identified a 14- amino acid human peptide, Human proIslet Peptide (HIP), consisting of the bioactive region in the human REG3a gene responsible for regenerating pancreatic islets, a process also known as islet neogenesis. "Utilizing an innovative and proprietary approach to evaluate the human genome and proteome from a physiologic perspective, we were able to identify a highly conserved bioactive gene product that triggers islet neogenesis. Restoring functional islets as a therapeutic approach is fundamental to curing the underlying disease," said Claresa S. Levetan, MD, FACE, Chief Medical Officer and Founder of CureDM, Inc.

CureDM has produced, stabilized and characterized this unique peptide in a variety of preclinical studies. In these studies, researchers have demonstrated that HIP stimulates insulin secretion in human pancreatic ductal tissue devoid of islets. HIP was also shown to stimulate new islet formation with a 3-fold increase in islet numbers in validated diabetic animal models compared to placebo, effectively reversing the disease in such animals. "Having demonstrated the preclinical proof of concept of this promising and novel therapeutic approach, we look forward to obtain regulatory approval and initiation of clinical testing of HIP in 2009," said H. Joseph Reiser Ph.D., Chief Executive Officer of CureDM.

The incidence of diabetes continues to grow at a double-digit rate worldwide with nearly 300 million patients estimated by 2030. At the time of diagnosis, islet mass is often reduced by 80% in type 1 patients and 50% in type 2 patients, supporting the importance of islet restoration as a therapeutic approach. Pancreatic islets contain four primary cell types and are responsible for producing insulin, amylin, glucagon and other hormones critical to maintaining normal glucose regulation. Current diabetes therapies, including insulin, help to control the disease but do not restore new islets. HIP addresses the underlying mechanism of the pathology of diabetes and represents a potentially curative approach to both, type 1 and 2 diabetes. If successful in human clinical trials, HIP-induced restoration of islet function has the potential to become a first-line treatment approach for diabetes and pre- diabetes.

About HIP

Human proIslet Peptide (HIP) is a 14-amino acid, stabilized human peptide that stimulates the signal pathways that induce new islet formation in the pancreas, without the use of stem cells. HIP creates new insulin-producing beta cells by generating new islets that contain alpha, beta, gamma and delta cells, all of which are necessary to regulate glucose metabolism. The core patent for the HIP technology was issued in July 2008.

About CureDM

CureDM is a Biotherapeutics company focusing on Diseases of Metabolism. CureDM has developed a proprietary platform technology using genomics and proteomics to identify bioactive components of gene products that are fundamental to address unmet medical needs. HIP is the first product derived from this process with other pipeline compounds under development. CureDM, Inc. is located in the Lankenau Institute for Medical Research at the Lankenau Hospital campus in Wynnewood, PA. For further information visit www.curedm.com

About Endocrine Practice

Endocrine Practice is the peer-reviewed journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists read by more than 6000 endocrinologists. The content of Endocrine Practice is covered by Index Medicus and EMBASE. For further information visit www.aace.com


'/>"/>
SOURCE CureDM, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. IDRI Collaborates with the Brazilian Butantan Institute To Develop Novel Vaccines Against Leishmaniasis
2. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
3. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
4. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
5. Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury
6. Medivation Presents New Data on Dimebons Novel Mechanism of Action
7. Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
8. Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
9. ScinoPharm Granted US Patent for Novel Crystal Forms
10. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
11. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Feb. 10, 2016  IsoRay, Inc. (NYSE MKT: ISR), ... and medical radioisotope applications for the treatment of prostate, ... announced its financial results for the second quarter and ... 2015. --> --> ... of fiscal 2016, which ended December 31, 2015, a ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a fully-integrated ... of two long-standing principal investigators (PI) to the roles of Chief Medical Officer, ... , Dr. Laurence Chu, a Benchmark Research PI in the Austin office, will ...
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare ... training and support program, Sonalinkā„¢ remote monitoring. The inaugural launch of this new ... February 5th, connecting Dr. Samuel Peretsman to a HIFU technical expert at SonaCare ...
(Date:2/10/2016)... ... February 10, 2016 , ... Global Stem Cells Group, ... Singapore-based Global Stem Cells Network (GSCN) and its affiliate Global Medical Training ... latest adipose and bone marrow therapies. , Through the new collaboration, Global ...
Breaking Biology Technology:
(Date:2/11/2016)... to new research from Acuity Market Intelligence, biometric ... iris, and eye-vein biometric smartphones have been introduced ... includes market leaders Apple, Samsung, Huawei, Xiaomi, TCL, ... million biometric smartphones are currently in use representing ... Maxine Most , Acuity Market Intelligence Principal, "This ...
(Date:2/11/2016)... LIVERMORE, Calif. , Feb. 11, 2016  Vigilant Solutions ... commercial LPR data are being used by Lee,s ... residents, including the recent location and arrest of a homicide ... Lee,s Summit covers around 65 square miles and ... Police Department has a single mobile license plate ...
(Date:2/10/2016)... , February 10, 2016 ... According to 2016 iris recognition market report, ... recognition is more widely accepted for border ... both fingerprint and iris recognition technology in ... to avoid purchasing two individual biometrics devices. ...
Breaking Biology News(10 mins):